| Effect of botulinum toxin A on proliferation and apoptosis in the T47D breast cancer cell line C Bandala, JLM Perez-Santos, E Lara-Padilla, MG Delgado Lopez, ... Asian Pacific Journal of Cancer Prevention 14 (2), 891-894, 2013 | 55 | 2013 |
| miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells M Anaya-Ruiz, C Bandala, JLM Pérez-Santos Asian Pacific Journal of Cancer Prevention 14 (6), 3757-3760, 2013 | 51 | 2013 |
| Alternative splicing in breast cancer and the potential development of therapeutic tools N Martínez-Montiel, M Anaya-Ruiz, M Pérez-Santos, ... Genes 8 (10), 217, 2017 | 42 | 2017 |
| miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line M Anaya-Ruiz, J Cebada, G Delgado-López, ML Sanchez-Vazquez, ... Asian Pacific journal of cancer prevention 14 (5), 2983-2986, 2013 | 38 | 2013 |
| An ecto-protein tyrosine phosphatase of Entamoeba histolytica induces cellular detachment by disruption of actin filaments in HeLa cells M Anaya-Ruiz, JLM Pérez-Santos, P Talamás-Rohana International journal for parasitology 33 (7), 663-670, 2003 | 37 | 2003 |
| Female breast cancer incidence and mortality in Mexico, 2000-2010 M Anaya-Ruiz, V Vallejo-Ruiz, L Flores-Mendoza, M Perez-Santos Asian Pacific Journal of Cancer Prevention 15 (3), 1477-1479, 2014 | 36 | 2014 |
| In vitro indomethacin administration upregulates interleukin‐12 production and polarizes the immune response towards a Th1 type in susceptible BALB/c mice infected with … JLM Pérez‐Santos, P Talamás‐Rohana Parasite immunology 23 (11), 599-606, 2001 | 32 | 2001 |
| Cervical cancer trends in Mexico: incidence, mortality and research output M Anaya-Ruiz, AK Vincent, M Perez-Santos Asian Pacific Journal of Cancer Prevention 15 (20), 8689-8692, 2014 | 31 | 2014 |
| LAG-3 antagonists by cancer treatment: a patent review M Perez-Santos, M Anaya-Ruiz, J Cebada, C Bandala, G Landeta, ... Expert opinion on therapeutic patents 29 (8), 643-651, 2019 | 23 | 2019 |
| Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1 I Herrera-Camacho, M Anaya-Ruiz, M Perez-Santos, L Millán-Pérez Peña, ... Expert opinion on therapeutic patents 29 (8), 587-593, 2019 | 23 | 2019 |
| Mexican breast cancer research output, 2003-2012 JLM Perez-Santos, M Anaya-Ruiz Asian Pacific Journal of Cancer Prevention 14 (10), 5921-5923, 2013 | 21 | 2013 |
| Bursera copallifera Extracts Have Cytotoxic and Migration-Inhibitory Effects in Breast Cancer Cell Lines F Domínguez, P Maycotte, A Acosta-Casique, S Rodríguez-Rodríguez, ... Integrative cancer therapies 17 (3), 654-664, 2018 | 15 | 2018 |
| OX40 agonists for cancer treatment: a patent review J Cebada, M Perez-Santos, C Bandala, E Lara-Padilla, ... Expert Opinion on Therapeutic Patents 31 (1), 81-90, 2021 | 14 | 2021 |
| Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649 M Perez-Santos, M Anaya-Ruiz, I Herrera-Camacho, L Millan-Perez Pena, ... Expert Opinion on Therapeutic Patents 29 (12), 921-924, 2019 | 13 | 2019 |
| Innovation status of gene therapy for breast cancer M Anaya-Ruiz, M Perez-Santos Asian Pacific Journal of Cancer Prevention 16 (9), 4133-4136, 2015 | 12 | 2015 |
| Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054 J Cebada, A Flores, C Bandala, I Lizaliturri-Flores, N Villa-Ruano, ... Expert Opinion on Therapeutic Patents 30 (7), 487-494, 2020 | 10 | 2020 |
| Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors M Perez-Santos Pharmaceutical Patent Analyst 9 (5), 149-154, 2020 | 8 | 2020 |
| Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739 L Millan-Perez Pena, PS Martin, I Herrera-Camacho, C Bandala, ... Expert Opinion on Therapeutic Patents 30 (5), 307-311, 2020 | 8 | 2020 |
| Neurophysiological mechanisms related to pain management in bone tumors P Romero-Morelos, E Ruvalcaba-Paredes, D Garciadiego-Cázares, ... Current Neuropharmacology 19 (3), 308-319, 2021 | 6 | 2021 |
| Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1 M Perez-Santos, M Anaya-Ruiz, J Cebada, I Herrera-Camacho Expert Opinion on Therapeutic Patents 29 (5), 311-314, 2019 | 6 | 2019 |
